Sobi™ publishes its report for the third quarter 2016,

Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) today
announces its results for the third quarter 2016. Revenue for the quarter
totalled SEK 1,171 M (786), an increase of 49 per cent compared to previous
year. Based on strong performance across the portfolio and an earlier launch for
Alprolix, the company has raised guidance for the full year.

Business highlights Q3 2016

  · Elocta® reimbursed in the UK, Italy, France and Spain
  · Alprolix® reimbursed in the UK
  · Long term Elocta and Alprolix data presented at WHF 2016 World Congress
  · Orfadin® capsule filing validated by Health Canada
  · Milan Zdravkovic appointed as SVP, Head of R&D

Financial highlights Q3 2016 (Q3 2015)

  · Total revenue of SEK 1,171 M (786), an increase of 49 per cent
  · Product revenue of SEK 1,009 M (645), an increase of 56 per cent (57 per
cent at CER)
  · Gross margin of 67 per cent (62)
  · EBITA of SEK 282 M (97)
  · Ended the quarter with a cash position of SEK 824 M
  · Earnings per share 0.53 SEK (0.02)

“Results in the third quarter had a positive contribution from the ongoing
launch of Elocta, from an earlier than anticipated launch for Alprolix and from
Kineret®. We continue to lay the foundation for a sustainable haemophilia
business in Europe with both Elocta and Alprolix gaining several important
reimbursement approvals in major markets”, said Geoffrey McDonough, CEO and
President at Sobi.

“A significant milestone after the quarter was the orphan designation approval
by the European Commission for our development candidate SOBI003 – a chemically
modified human recombinant sulfamidase for the treatment of
mucopolysaccharidosis type IIIA (Sanfilippo A syndrome). MPS IIIA is a severe
and debilitating disease with devastating consequences for patients, and there
is presently no treatment available.”

  Financial
  Summary
                  Q3     Q3            Jan    Jan            Full year
                                       -Sep   -Sep
  Amounts in SEK  2016   2015  Change  2016   2015   Change  2015
  M
  Total           1 171  786   49%     3 913  2 414  62%     3 228
  revenues1
  Gross profit    782    486   61%     2 791  1 486  88%     2 007

  Gross margin    67%    62%           71%    62%            62%
  EBITA           282    97    >100%   1 334  343    >100%   433

  EBIT            171    25    >100%   1 034  129    >100%   146
  (Operating
  profit/loss)
  Profit/loss     143    5     >100%   710    77     >100%   68
  for the period
  1Jan-Sep 2016
  revenues
  include a one
  -time credit
  in Q1 of SEK
  322 M relating
  to the first
  commercial
  sales of
  Elocta, and a
  one-time
  credit in Q2
  of SEK 386 M
  relating to
  first
  commercial
  sales of
  Alprolix.

Outlook 2016 – guidance raised

For the full-year 2016, Sobi now expects revenues of SEK 5,125—5,200 M (4,800
-5,000). Revenues include one-time credits for Elocta of SEK 322 M and for
Alprolix of SEK 386 M which do not impact cash. Gross margin is now expected to
be 70 per cent (68-70) and EBITA for the full-year in the range of SEK
1,475–1,525 M (1,200-1,300).

The original outlook was published 29 February 2016.

---

Sobi's report for the third quarter 2016 can be found on
http://www.sobi.com/Investors--Media/Financial-Reports/

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products across Europe, the Middle
East, North Africa and Russia for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on
Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations             Investor relations
Linda Holmström, Senior     Jörgen Winroth, Vice
Communications Manager      President, Head of Investor
                            Relations
+46 70 873 40 95            +1 347-224-0819, +1 212-579
                            -0506, +46 8 697 2135
 linda.holmstrom@sobi.com   jorgen.winroth@sobi.com

Sobi announces the information set out in this press release pursuant to the
Swedish Securities Market Act. The information was submitted for publication at
08:00 CET on 27 October 2016.
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00     www.sobi.com
Sobi™ publishes its report for the third quarter 2016, raises guidance

Attachments
